BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8939245)

  • 1. Untreated lung cancer: quantification of systematic distortion of tumor size and shape on non-attenuation-corrected 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET scans.
    Zasadny KR; Kison PV; Quint LE; Wahl RL
    Radiology; 1996 Dec; 201(3):873-6. PubMed ID: 8939245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings.
    Frank A; Lefkowitz D; Jaeger S; Gobar L; Sunderland J; Gupta N; Scott W; Mailliard J; Lynch H; Bishop J
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1495-512. PubMed ID: 7635795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET.
    Minn H; Zasadny KR; Quint LE; Wahl RL
    Radiology; 1995 Jul; 196(1):167-73. PubMed ID: 7784562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lesion-to-background ratio in nonattenuation-corrected whole-body FDG PET images.
    Imran MB; Kubota K; Yamada S; Fukuda H; Yamada K; Fujiwara T; Itoh M
    J Nucl Med; 1998 Jul; 39(7):1219-23. PubMed ID: 9669398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling.
    Steinert HC; Hauser M; Allemann F; Engel H; Berthold T; von Schulthess GK; Weder W
    Radiology; 1997 Feb; 202(2):441-6. PubMed ID: 9015071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors.
    Inoue T; Kim EE; Wong FC; Yang DJ; Bassa P; Wong WH; Korkmaz M; Tansey W; Hicks K; Podoloff DA
    J Nucl Med; 1996 Sep; 37(9):1472-6. PubMed ID: 8790196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer.
    Sazon DA; Santiago SM; Soo Hoo GW; Khonsary A; Brown C; Mandelkern M; Blahd W; Williams AJ
    Am J Respir Crit Care Med; 1996 Jan; 153(1):417-21. PubMed ID: 8542152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cancer detection with whole-body FDG PET images without attenuation correction].
    Yasuda S; Ide M; Takagi S; Shohtsu A; Mitomi T; Kobayashi S; Suzuki Y
    Kaku Igaku; 1996 Apr; 33(4):367-73. PubMed ID: 8683875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation.
    Wahl RL; Quint LE; Greenough RL; Meyer CR; White RI; Orringer MB
    Radiology; 1994 May; 191(2):371-7. PubMed ID: 8153308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies.
    Shulkin BL; Mitchell DS; Ungar DR; Prakash D; Dole MG; Castle VP; Hernandez RJ; Koeppe RA; Hutchinson RJ
    Radiology; 1995 Feb; 194(2):495-500. PubMed ID: 7824731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer.
    Higashi K; Nishikawa T; Seki H; Oguchi M; Nambu Y; Ueda Y; Yuasa K; Tonami H; Okimura T; Yamamoto I
    J Nucl Med; 1998 Jan; 39(1):9-15. PubMed ID: 9443730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
    Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual-head gamma camera 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography in oncological patients: effects of non-uniform attenuation correction on lesion detection.
    Zimny M; Kaiser HJ; Cremerius U; Reinartz P; Schreckenberger M; Sabri O; Buell U
    Eur J Nucl Med; 1999 Aug; 26(8):818-23. PubMed ID: 10436193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG imaging of lung nodules: a phantom study comparing SPECT, camera-based PET, and dedicated PET.
    Coleman RE; Laymon CM; Turkington TG
    Radiology; 1999 Mar; 210(3):823-8. PubMed ID: 10207487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation.
    Wahl RL; Zasadny K; Helvie M; Hutchins GD; Weber B; Cody R
    J Clin Oncol; 1993 Nov; 11(11):2101-11. PubMed ID: 8229124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of malignancies with SPECT versus PET, with 2-[fluorine-18]fluoro-2-deoxy-D-glucose.
    Martin WH; Delbeke D; Patton JA; Sandler MP
    Radiology; 1996 Jan; 198(1):225-31. PubMed ID: 8539384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer.
    Brown RS; Leung JY; Kison PV; Zasadny KR; Flint A; Wahl RL
    J Nucl Med; 1999 Apr; 40(4):556-65. PubMed ID: 10210213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cancer screening with whole-body FDG PET].
    Yasuda S; Ide M; Takagi S; Shohtsu A
    Kaku Igaku; 1996 Oct; 33(10):1065-71. PubMed ID: 8952258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detecting recurrent or residual lung cancer with FDG-PET.
    Inoue T; Kim EE; Komaki R; Wong FC; Bassa P; Wong WH; Yang DJ; Endo K; Podoloff DA
    J Nucl Med; 1995 May; 36(5):788-93. PubMed ID: 7738649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography.
    Glantz MJ; Hoffman JM; Coleman RE; Friedman AH; Hanson MW; Burger PC; Herndon JE; Meisler WJ; Schold SC
    Ann Neurol; 1991 Apr; 29(4):347-55. PubMed ID: 1929205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.